Abstract
Background Aim of the current study was to systematically review and to conduct meta-analysis on the published pre-clinical studies of MSC treatment in COPD animal models
Methods: and Results Statistical analysis was performed using the Comprehensive Meta-Analysis software (Version 3). The pooled Hedges's g with 95% confidence intervals (95% CIs) was adopted to assess the effect size. Random effect model was used due to the heterogeneity between the studies. A total of 20 eligible studies were included in the current systematic review and overall meta-analysis showed that MSC administration was significantly in favor of attenuating acute lung injury (Hedges's g = -2.325 ± 0.145 with 95% CI: -2.609 ∼ -2.040, P< 0.001 for mean linear intercept, MLI; Hedges's g = -3.488 ± 0.504 with 95% CI: -4.476 ∼ -2.501, P< 0.001 for TUNEL staining), stimulating lung tissue repair (Hedges's g = 3.249 ± 0.586 with 95% CI: 2.103∼ 4.394, P < 0.001) and improving lung function (Hedges's g = 2.053 ± 0.408 with 95% CI: 1.253 ∼ 2.854, P< 0.001). The mechanism of MSC therapy in COPD seems to be ameliorating airway inflammation (Hedges's g = -2.956 ± 0.371 with 95% CI: -3.683 ∼ -2.229, P< 0.001) and stimulating cytokine synthesis that involves in lung tissue repair (Hedges's g = 3.103 ± 0.734 with 95% CI: 1.664 ∼ 4.541, P< 0.001)
Conclusion: These pre-clinical studies demonstrated that MSC hold promise in the treatment of chronic lung diseases including COPD. The mechanisms of MSCs in pre-clinical COPD treatment may be associated with attenuating airway inflammation as well as stimulating lung tissue repair.
- Copyright ©the authors 2016
